Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1

SMA Clinical Trial

— STRIVE-EU  

Official title:

Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03461289
• Other study ID #: AVXS-101-CL-302
• Secondary ID: 2017-000266-29CO
• Status: Completed
• Phase: Phase 3
• Start date: August 16, 2018
• Est. completion date: September 11, 2020

Study information

• Verified date: August 2022
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are genetically defined by a biallelic pathogenic mutation of the survival motor neuron 1 gene (SMN1) with one or two copies of survival motor neuron 2 gene (SMN2). Up to 30 patients < 6 months (< 180 days) of age at the time of gene replacement therapy (Day 1) will be enrolled.

Description:

Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are genetically defined by a biallelic pathogenic mutation of the survival motor neuron 1 gene (SMN1) with one or two copies of survival motor neuron 2 gene (SMN2). 30 patients < 6 months (< 180 days) of age at the time of gene replacement therapy (Day 1) will be enrolled.

The trial includes a screening period, a gene replacement therapy period, and a follow-up period. During the screening period (Days -30 to -2), patients whose parent(s)/legal guardian(s) provide informed consent will complete screening procedures to determine eligibility for trial enrollment. Patients who meet the entry criteria will enter the in-patient gene replacement therapy period (Day -1 to Day 3). On Day -1, patients will be admitted to the hospital for pre-treatment baseline procedures. On Day 1, patients will receive a one-time intravenous (IV) infusion of onasemnogene abeparvovec-xioi, and will undergo in-patient safety monitoring over the next 48 hours. Patients may be discharged 48 hours after the infusion, based on Investigator judgment. During the outpatient follow-up period (Days 4 to End of Trial at 18 months of age), patients will return at regularly scheduled intervals for efficacy and safety assessments until the End of Trial when the patient reaches 18 months of age. After the End of Trial visit, eligible patients will be asked to participate into the long-term follow up trial.

All post-treatment visits will be relative to the date on which gene replacement therapy is administered, until the patient is 14 months of age, after which they will be relevant to the patient's date of birth.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: September 11, 2020
• Est. primary completion date: September 11, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 6 Months

Eligibility

Inclusion Criteria:

• Patients with SMA Type 1 as determined by diagnosis of SMA based on gene mutation analysis with biallelic SMN1 mutations (deletion or point mutations) and one or two copies of SMN2 [inclusive of the known SMN2 gene modifier mutation (c.859G>C)]

• Patients must be < 6 months (< 180 days) of age at the time of onasemnogene abeparvovec-xioi infusion

• Patients must have a swallowing evaluation test performed prior to administration of gene replacement therapy

Exclusion Criteria:

• Previous, planned or expected scoliosis repair surgery/procedure prior to 18 months of age

• Use of invasive ventilatory support (tracheotomy with positive pressure) or pulse oximetry < 95% saturation at screening

• Use or requirement of non-invasive ventilatory support for 12 or more hours daily in the two weeks prior to dosing

• Patient with signs of aspiration based on a swallowing test or whose weight-for-age falls below the 3rd percentile based on World Health Organization (WHO) Child Growth Standards and unwilling to use an alternative method to oral feeding

• Participation in recent SMA treatment clinical trial (with the exception of observational cohort studies or non-interventional studies) or receipt of an investigational or commercial compound, product or therapy administered with the intent to treat SMA (eg, nusinersen, valproic acid,) at any time prior to screening for this trial.

Related Conditions & MeSH terms

• Atrophy
• Muscular Atrophy
• Muscular Atrophy, Spinal
• SMA

Intervention

Biological:
• Onasemnogene Abeparvovec-xioi
Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken ß-actin-hybrid promoter (CB).

Locations

Country	Name	City	State
Belgium	University Hospital Ghent Neuromuscular reference center	Ghent
Belgium	Neuropédiatrie - Centre de Référence des Maladies Neuromusculaires	Liège
France	Hôpital Armand Trousseau	Paris
Italy	Istituto Gianninia Gaslini	Genova
Italy	Policlinico "G. Martino"	Messina
Italy	Carlo Besta Neurological Research Institute	Milan
Italy	University of Milan	Milan
Italy	Policlinico Gemelli	Rome
United Kingdom	Great Ormond Street Hospital for Children	London
United Kingdom	The John Walton Muscular Dystrophy Research Centre MRC Centre for Neuromuscular Diseases at Newcastle	Newcastle Upon Tyne

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Gene Therapies

Countries where clinical trial is conducted

Belgium,  France,  Italy,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Achieve Independent Sitting for at Least 10 Seconds	Independent sitting is defined by the World Health Organization Multicentre Growth Reference Study, confirmed by video recording, as a participant who sits up straight with head erect for at least 10 seconds; participant does not use arms or hands to balance body or support position.	From Day 1 up to 18 Months of Age Visit (Up to a Maximum of Approximately 17 Months)
Secondary	Event-free Survival at 14 Months of Age	Event-free survival at 14 months of age was defined as the number of participants who did not die, did not require permanent ventilation and did not withdraw from the study by 14 months of age.	Up to 14 months of age

External Links

•   patient recruitment website
•   The Novartis Clinical Trial Results